| [1] |
SANGRO B, SAROBE P, HERVÁS-STUBBS S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8): 525-543. DOI: 10.1038/s41575-021-00438-0. |
| [2] |
CREELAN BC, WANG C, TEER JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J]. Nat Med, 2021, 27(8): 1410-1418. DOI: 10.1038/s41591-021-01462-y. |
| [3] |
HUANG H, NIE CP, LIU XF, et al. Phase Ⅰ study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer[J]. J Clin Invest, 2022, 132(15): e157726. DOI: 10.1172/JCI157726. |
| [4] |
KRISTENSEN NP, HEEKE C, TVINGSHOLM SA, et al. Neoantigen-reactive CD8 + T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma[J]. J Clin Invest, 2022, 132(2): e150535. DOI: 10.1172/JCI150535. |
| [5] |
JIANG SS, TANG Y, ZHANG YJ, et al. A phase Ⅰ clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma[J]. Oncotarget, 2015, 6(38): 41339-41349. DOI: 10.18632/oncotarget.5463. |
| [6] |
WOLF NK, KISSIOV DU, RAULET DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy[J]. Nat Rev Immunol, 2023, 23(2): 90-105. DOI: 10.1038/s41577-022-00732-1. |
| [7] |
HOOGSTAD-VAN EVERT J, BEKKERS R, OTTEVANGER N, et al. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase Ⅰ study)[J]. Medicine (Baltimore), 2019, 98(5): e14290. DOI: 10.1097/MD.0000000000014290. |
| [8] |
BAE WK, LEE BC, KIM HJ, et al. A phase Ⅰ study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma[J]. Front Immunol, 2022, 13: 879452. DOI: 10.3389/fimmu.2022.879452. |
| [9] |
CICHOCKI F, VAN DER STEGEN S, MILLER JS. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies[J]. Blood, 2023, 141(8): 846-855. DOI: 10.1182/blood.2022016205. |
| [10] |
SHI M, LI YY, XU RN, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial[J]. Hepatol Int, 2021, 15(6): 1431-1441. DOI: 10.1007/s12072-021-10199-2. |
| [11] |
WANG L, LI J, LIU H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28 (Suppl 1): 85-92. DOI: 10.1111/jgh.12029. |
| [12] |
SALAMA H, ZEKRI AR, MEDHAT E, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease[J]. Stem Cell Res Ther, 2014, 5(3): 70. DOI: 10.1186/scrt459. |
| [13] |
ZHANG Y, ZHANG J, YI H, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase Ⅰ/Ⅱ randomized, open-label, controlled trial[J]. Stem Cell Res Ther, 2021, 12(1): 244. DOI: 10.1186/s13287-021-02246-4. |
DownLoad: